Literature DB >> 10721041

Use of melatonin in the treatment of phase shift and sleep disorders.

D J Skene1, S W Lockley, J Arendt.   

Abstract

When administered to humans the pineal hormone melatonin can phase shift a number of circadian rhythms. This property has prompted the investigation of exogenous melatonin in sleep disorders known to have an underlying chronophysiological basis (i.e. circadian rhythm sleep disorders). Both in field and simulated studies of jet lag and shift work suitably timed melatonin improved sleep and, in some cases, hastened readaptation of the circadian rhythms following the phase shift. Melatonin treatment has also been evaluated in the circadian sleep disorders: delayed sleep phase syndrome (DSPS) and non-24-hour sleep wake disorder. Compared with placebo, melatonin advanced the sleep period in subjects with DSPS. Melatonin also improved a number of sleep parameters in blind subjects suffering from non-24-hour sleep wake disorder.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10721041     DOI: 10.1007/978-1-4615-4709-9_10

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  10 in total

1.  Urinary metabolites and antioxidant products of exogenous melatonin in the mouse.

Authors:  Xiaochao Ma; Jeffrey R Idle; Kristopher W Krausz; Dun-Xian Tan; Leopoldo Ceraulo; Frank J Gonzalez
Journal:  J Pineal Res       Date:  2006-05       Impact factor: 13.007

Review 2.  Light, timing of biological rhythms, and chronodisruption in man.

Authors:  Thomas C Erren; Russel J Reiter; Claus Piekarski
Journal:  Naturwissenschaften       Date:  2003-10-14

3.  Combination of light and melatonin time cues for phase advancing the human circadian clock.

Authors:  Tina M Burke; Rachel R Markwald; Evan D Chinoy; Jesse A Snider; Sara C Bessman; Christopher M Jung; Kenneth P Wright
Journal:  Sleep       Date:  2013-11-01       Impact factor: 5.849

Review 4.  Systems Chronotherapeutics.

Authors:  Annabelle Ballesta; Pasquale F Innominato; Robert Dallmann; David A Rand; Francis A Lévi
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

5.  Pituitary hormone circadian rhythm alterations in cirrhosis patients with subclinical hepatic encephalopathy.

Authors:  Dimitrios Velissaris; Menelaos Karanikolas; Andreas Kalogeropoulos; Ekaterini Solomou; Panagiotis Polychronopoulos; Konstantinos Thomopoulos; Chrissoula Labropoulou-Karatza
Journal:  World J Gastroenterol       Date:  2008-07-14       Impact factor: 5.742

6.  Melatonin ameliorates cerebral vasospasm after experimental subarachnoidal haemorrhage correcting imbalance of nitric oxide levels in rats.

Authors:  M A Aladag; Y Turkoz; H Parlakpinar; H Ozen; M Egri; S C Unal
Journal:  Neurochem Res       Date:  2009-05-05       Impact factor: 3.996

7.  Therapeutic applications of melatonin.

Authors:  Ifigenia Kostoglou-Athanassiou
Journal:  Ther Adv Endocrinol Metab       Date:  2013-02       Impact factor: 3.565

8.  Melatonin's Effect on the Efficacy of Desmopressin in the Treatment of Enuresis.

Authors:  Pietro Ferrara; Annamaria Sbordone; Costanza Cutrona; Francesca Ianniello; Chiara Guadagno; Giacomo Perrone; Antonio Chiaretti; Alberto Verrotti; Vincenzo Di Lazzaro
Journal:  Int Neurourol J       Date:  2016-09-23       Impact factor: 2.835

9.  Chronotypology and melatonin alterations in minimal hepatic encephalopathy.

Authors:  Dimitrios Velissaris; Vasilis Karamouzos; Panagiotis Polychronopoulos; Menelaos Karanikolas
Journal:  J Circadian Rhythms       Date:  2009-05-29

10.  New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists.

Authors:  Rüdiger Hardeland
Journal:  Neuropsychiatr Dis Treat       Date:  2009-06-10       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.